Matching-adjusted indirect comparisons of bispecific antibodies in R/R FL
Presented by Prof Alexey Danilov (City of Hope National Medical Center, Duarte, CA, USA)
Epcoritamab (EPCOR) is a novel, subcutaneous CD3xCD20 bispecific antibody (bsAb) that has demonstrated deep and durable responses with manageable safety in patients with R/R FL following at least two systemic therapies, as evidenced by the EPCORE NHL-1 trial. Intravenous mosunetuzumab (MOSUN) and intravenous odronextamab (ODRO) are also CD20xCD3 bsAbs that have shown efficacy and safety in the same patient population, based on findings from the GO29781 and ELM-2 trials, respectively. To date, no direct comparisons of the efficacy and safety of these bsAbs have been conducted.
Professor Alexey Danilov, a haematologist at the City of Hope National Medical Center in Duarte, CA, USA, presented the outcomes of matching-adjusted indirect comparisons of the efficacy and safety of EPCOR versus MOSUN or ODRO in patients with R/R FL after at least two systemic therapies.
References:
Danilov A, EHA2024. #P1121
With the educational support of:
